Proof of Usefulness Report

Auron Therapeutics Inc.

Analysis completed on 1/28/2026

+358
Proof of Usefulness Score
Certified Problem Solver

Auron Therapeutics is a verified, high-potential Series B biotechnology company (raised ~$104M) developing novel oncology therapies (IND cleared for AUTX-703). However, the project submission itself contains significant inaccuracies and low-quality data (e.g., claiming 'everyone' as audience and 'most people' have used it, which contradicts its clinical stage). The 'marketcap: 500000' entry likely omits zeros (possibly intending $500M valuation). The score reflects the high verifiable utility and innovation of the entity, penalized by the poor quality and dubious claims of the submission form.

Ready to Compete for $150k+ in Prizes?

Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes

View All Reports

Score Breakdown

Real World Utility+108.0
Audience Reach Impact+32.0
Technical Innovation+81.0
Evidence Of Traction+76.0
Market Timing Relevance+36.0
Functional Completeness+1.0
Subtotal+334
Usefulness Multiplierx1.07
Final Score+358

Project Details

Project URL
Description
Auron Therapeutics is a privately held patient-centered, platform-powered, product-driven oncology company. We are the leaders in identifying and targeting cell state to treat a range of solid tumors and hematological malignancies.

Algorithm Insights

Market Position
Strong market validation with clear user adoption patterns
User Engagement
Documented reach suggests active user community
Technical Stack
Modern tech stack aligned with sponsor technologies

Recommendations to Increase Usefulness Score

Document User Growth

Provide specific metrics on user acquisition and retention rates

Showcase Revenue Model

Detail sustainable monetization strategy and current revenue streams

Expand Evidence Base

Include testimonials, case studies, and third-party validation

Technical Roadmap

Share development milestones and feature completion timeline